| Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing solutions for people suffering from acute cannabinoid intoxication (ACI) and addiction. Co.'s primary product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, to address the unmet medical need for an antidote for ACI. ANEB-001 is an orally bioavailable absorbed treatment that will reverse the symptoms of ACI. Co.'s proprietary position in the treatment of ACI is protected by rights to several patent applications covering various methods of use of the compound and delivery systems. We show 6 historical shares outstanding datapoints in our ANEB shares outstanding history coverage, used to compute ANEB market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ANEB market cap history over the course of time is important for investors
interested in comparing ANEB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ANEB versus a peer is one thing; comparing
ANEB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ANEB can fluctuate over the course of history.
With this page we aim to empower investors researching ANEB by allowing them to research the ANEB market cap history.